本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Genetic Technologies Ltd

0.039
0.000
成交量:- -
成交額:- -
市值:5,208.15萬
市盈率:-0.43
高:0.039
開:0.039
低:0.039
收:0.039
資料載入中...

公司資料

公司名字:
Genetic Technologies Ltd
交易所:
ASX
成立時間:
1987
員工人數:
- -
公司地址:
T1 404 Kon-Tiki Business Centre,55 Plaza Parade,Maroochydore,Queensland,Australia
郵編:
4558
傳真:
- -
簡介:
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.